The HERMES study, a randomized trial of just 46 patients presented at ESTRO 2026, demonstrates that extreme hypofractionation delivering the full therapeutic dose in only two MRI-guided sessions spaced over eight days produces urinary and bowel toxicity profiles indistinguishable from the current five-fraction standard. While the original MedicalXpress coverage emphasizes patient convenience, it underplays the trial’s methodological constraints: at two-year follow-up the cohort remains too small and immature to detect rare late effects or confirm non-inferiority on cancer control. Prior phase-III evidence from the HYPO-RT-PC and CHHiP trials already established that moderate hypofractionation (20 fractions) is safe; HERMES extends this logic to two fractions using real-time MRI tracking to spare rectum and bladder. Yet the absence of reported biochemical recurrence rates and the reliance on a single-center, industry-supported platform raise questions about generalizability. Health-system modeling suggests two-fraction regimens could cut radiotherapy department workload by 60 percent, but only if longer-term data from ongoing larger SBRT trials (PACE, NRG-GU005) replicate these early toxicity findings without increased second malignancies.